Sangani Hospitals Limited (SANGANI)
SANGANI delivery percentage
NSE end-of-day data for
On Thu, 22 Oct 2026, 100.0% of the SANGANI shares traded on NSE were taken to delivery, against the stock's own 20-session average of 93.57%. That is close to its usual level. Turnover was only ₹2 lakh, so a handful of trades can move this figure. Volume was 0.2 times its average, well below normal. It closed at its lower price band (circuit) on 22 Oct, one of 9 band closes in about the last 20 sessions.
Delivery in the last 5 sessions: 93.3% · 100.0% · 75.0% · 100.0% · 100.0%
A description of what the exchange published, not a recommendation. Names such as "accumulation" or "long buildup" label a pattern in the numbers. How delivery is analysed
📢 Recent Corporate Announcements
Sangani Hospitals Limited reported the voting results of its 5th Annual General Meeting held on September 28, 2026. All three ordinary resolutions, including the adoption of FY26 financial statements, the re-appointment of director Rajeshkumar Sangani, and the appointment of statutory auditors for a 5-year term, were passed with 100% of the polled votes in favor. A total of 10,037,490 votes were cast (representing 99.28% of total outstanding shares), with zero votes against. Attendance at the meeting remained concentrated, with only 11 shareholders (7 promoters and 4 public) voting in person or through proxy.
- All 3 ordinary resolutions passed unanimously with 100% votes in favor (10,037,490 votes).
- Overall voter turnout stood at 99.28% of outstanding shares (10,037,490 votes polled out of 13,776,990 shares).
- Promoter voting participation was 98.22% (10,025,490 shares polled out of 10,206,990 promoter shares).
- Meeting participation comprised 11 shareholders in person/proxy (7 promoter, 4 public) out of 453 total shareholders.
Sangani Hospitals Limited has scheduled its 5th Annual General Meeting (AGM) on Monday, September 28, 2026, at its registered office in Keshod, Gujarat. The agenda includes the adoption of audited financial statements for FY26 and the re-appointment of director Rajeshkumar Sangani who retires by rotation. Shareholders will also consider approving the appointment of M/s. R G G R and Associates LLP as statutory auditors for a 5-year term ending in 2031. Being listed on the NSE SME platform, the company is exempt from offering e-voting facilities.
- 5th Annual General Meeting scheduled for September 28, 2026 at 1:30 PM IST
- Proposed appointment of M/s. R G G R and Associates LLP as Statutory Auditors for a 5-year term up to 2031
- Re-appointment of Whole Time Director Rajeshkumar Sangani, who holds 33,21,663 equity shares and retires by rotation
- Adoption of standalone and consolidated audited financial statements for the financial year ended March 31, 2026
Sangani Hospitals Limited held its Board Meeting on September 3, 2026, approving several routine governance matters. The Board approved the Board Report for FY 2025-26 and proposed the appointment of M/s. R G G R & Associates LLP as Statutory Auditors for a 5-year term, subject to shareholder approval. Additionally, the re-appointment of retiring director Mr. Rajeshkumar Sangani was approved for voting. The 5th Annual General Meeting (AGM) has been scheduled for Saturday, September 28, 2026, at the company's registered office in Keshod.
- Appointed M/s. R G G R & Associates LLP as Statutory Auditors for a period of 5 years, subject to shareholder approval
- Scheduled the 5th Annual General Meeting for Saturday, September 28, 2026, at 1.30 p.m.
- Approved the Board Report and annexures for the financial year ended March 31, 2026
- Approved the re-appointment of Mr. Rajeshkumar Sangani, Whole Time Director, retiring by rotation
Sangani Hospitals Limited has submitted its Structured Digital Database (SDD) compliance certificate for the quarter ended June 30, 2026. The company secretary confirmed that the database is non-tamperable, maintained internally, and capable of storing records for 8 years. During the quarter, the company identified and recorded 1 specific event involving Unpublished Price Sensitive Information (UPSI). No instances of non-compliance were reported, indicating adherence to SEBI's Prohibition of Insider Trading (PIT) regulations.
- 1 event involving UPSI was required to be captured and was successfully recorded during the quarter.
- The SDD system is designed to maintain records for a period of 8 years as per regulatory requirements.
- Zero non-compliance issues were observed during the reporting period ended June 30, 2026.
- The company has spent ₹ 5.37 Cr out of an ₹ 8.10 Cr budget for the Keshod Hospital expansion as per recent context.
Financial Performance
Revenue Growth by Segment
Consolidated revenue from operations grew by 104.55% YoY to INR 20.47 Cr for the half-year ended September 30, 2025, compared to INR 10.01 Cr in the previous year's corresponding period. Standalone sales and other income for FY24 grew 11.07% to INR 13.05 Cr.
Geographic Revenue Split
100% of revenue is derived from Gujarat, India, specifically from hospital operations in Keshod and pharmaceutical distribution via its subsidiary.
Profitability Margins
Consolidated Net Profit Margin for the half-year ended September 30, 2025, was 4.84%, a significant decline from 15.86% in the same period of the previous year. FY24 standalone net profit was INR 2.70 Cr (20.6% margin).
EBITDA Margin
Consolidated Profit Before Tax (PBT) margin for HY Sept 2025 stood at 6.26% (INR 1.30 Cr) compared to 21.17% (INR 2.28 Cr) in HY Sept 2024, indicating a sharp rise in operating costs relative to revenue.
Capital Expenditure
The company has projected a total capital expenditure of INR 8.10 Cr for the expansion of the Keshod Hospital. As of September 30, 2025, INR 5.37 Cr has been utilized for this expansion.
Credit Rating & Borrowing
Not disclosed in available documents; however, finance costs were reported as zero for the half-year ended September 30, 2025, suggesting minimal interest-bearing debt.
Operational Drivers
Raw Materials
Medical consumables and pharmaceutical stock-in-trade represent the primary inputs, accounting for 63.37% of total revenue (INR 13.11 Cr) for the half-year ended September 30, 2025.
Import Sources
Primarily sourced from domestic distributors within Gujarat and other Indian states to support hospital and pharmacy operations.
Key Suppliers
Ankur Distributors (subsidiary) handles a portion of pharmaceutical procurement; other specific third-party medical suppliers are not named.
Capacity Expansion
Current expansion is focused on the Keshod Hospital facility (INR 5.37 Cr spent of INR 8.10 Cr budget) and a planned expansion in Veraval to increase bed capacity and service range.
Raw Material Costs
Purchases of stock-in-trade increased by 264.35% YoY to INR 13.11 Cr in HY Sept 2025, significantly outpacing revenue growth and impacting overall profitability.
Manufacturing Efficiency
Capacity utilization metrics for hospital beds are not disclosed, but depreciation increased to INR 0.34 Cr in HY Sept 2025, reflecting new asset commissioning.
Logistics & Distribution
Distribution costs are integrated into the pharmaceutical segment's operating expenses; specific logistics percentages are not disclosed.
Strategic Growth
Growth Strategy
Growth is targeted through the expansion of existing hospital infrastructure in Keshod and Veraval using IPO proceeds. The strategy includes increasing bed capacity, enhancing diagnostic capabilities, and leveraging the pharmaceutical distribution network of Ankur Distributors.
Products & Services
Healthcare services including inpatient and outpatient treatments, surgical procedures, diagnostic services, and pharmaceutical products sold through retail and wholesale channels.
Brand Portfolio
Sangani Hospitals, Ankur Distributors.
New Products/Services
Expansion of specialized medical departments in the Keshod facility is expected to contribute to higher average revenue per occupied bed (ARPOB).
Market Expansion
Expansion into the Veraval region is a key objective of the IPO proceeds to capture regional healthcare demand in coastal Gujarat.
Market Share & Ranking
Not disclosed; operates as a regional healthcare provider in the Saurashtra region of Gujarat.
Strategic Alliances
The company operates with its subsidiary, Ankur Distributors, to integrate the healthcare supply chain.
External Factors
Industry Trends
The healthcare sector is shifting toward technology-driven delivery and increased insurance penetration. Sangani is positioning itself by upgrading infrastructure to meet evolving patient needs in semi-urban areas.
Competitive Landscape
Competes with local private clinics and government hospitals in the Junagadh and Veraval districts.
Competitive Moat
The company's moat is based on its established regional presence and the high 'switching cost' associated with trusted local medical practitioners. Sustainability depends on maintaining clinical outcomes and managing rising procurement costs.
Macro Economic Sensitivity
Highly sensitive to healthcare spending trends in India and changes in government health schemes (e.g., Ayushman Bharat) which can affect patient volumes and reimbursement rates.
Consumer Behavior
Increasing preference for organized healthcare facilities over smaller clinics in rural and semi-urban India.
Geopolitical Risks
Low direct impact, though global supply chain disruptions can affect the pricing of imported medical equipment and specialized drugs.
Regulatory & Governance
Industry Regulations
Subject to the Clinical Establishments Act, bio-medical waste management norms, and pharmaceutical distribution licensing requirements.
Environmental Compliance
Must comply with bio-medical waste management rules; specific compliance costs are not disclosed.
Taxation Policy Impact
Effective tax rate for HY Sept 2025 was approximately 22.4% (INR 0.29 Cr tax on INR 1.30 Cr PBT).
Legal Contingencies
The secretarial audit for FY24 did not report any major pending litigations, though management notes that factors like litigation could influence future results.
Risk Analysis
Key Uncertainties
The primary uncertainty is the recoverability of trade receivables, which grew from INR 2.95 Cr to INR 13.29 Cr in six months, potentially impacting liquidity.
Geographic Concentration Risk
High risk as 100% of operations are concentrated in the Junagadh/Keshod region of Gujarat, making the company vulnerable to regional economic or regulatory shifts.
Third Party Dependencies
Dependent on medical professionals and specialists; inability to retain key talent could disrupt specialized healthcare services.
Technology Obsolescence Risk
Risk of medical equipment becoming outdated; requires continuous reinvestment in diagnostic and surgical technology.
Credit & Counterparty Risk
Significant exposure to insurance companies and government health schemes, which often have longer payment cycles, contributing to the high receivables balance.
